Omnicell, Inc. reported fiscal 2025 revenue of $1.185 billion, a 7% increase from $1.112 billion in 2024. The growth was driven by a 1% decline in product revenue, offset by an 8% rise in service revenue, reflecting the company’s shift toward higher‑margin recurring services.
The company posted a GAAP net loss of $2 million ($0.05 per diluted share) for the year, compared with a GAAP net income of $16 million ($0.34 per diluted share) in 2024. Non‑GAAP net income fell to $18 million ($0.40 per diluted share) from $28 million ($0.60 per diluted share) in the prior year, while non‑GAAP EBITDA declined to $140 million from $136 million. The 4‑percentage‑point drop in non‑GAAP gross margin—from 47.4% in Q4 2024 to 43.2% in Q4 2025—was largely driven by a $7 million tariff impact on Chinese‑manufactured components and a shift toward lower‑margin product mix.
Non‑GAAP earnings per share of $0.40 missed the consensus estimate of $0.51 by $0.11, a 21% shortfall. The miss was primarily due to the tariff‑related cost increase and the weaker product mix, which reduced pricing power. Analysts had expected a higher EPS because of the company’s recent service‑revenue expansion and the launch of the Titan XT system, which was anticipated to lift margins.
For 2026, Omnicell guided total revenue of $1.215 billion to $1.255 billion, product revenue of $690 million to $710 million, and service revenue of $525 million to $545 million. Non‑GAAP EBITDA guidance of $145 million to $160 million and non‑GAAP EPS of $1.65 to $1.85 signal management’s confidence in stabilizing margins after the tariff headwinds ease, but the revenue range is below the analyst consensus of $1.26 billion, indicating a cautious outlook.
The company cited ongoing tariff costs and a product‑mix shift as short‑term headwinds, while highlighting the continued growth of recurring service revenue and the expected easing of tariff impacts in 2026. CEO Randall Lipps emphasized that the company remains focused on executing its strategic priorities, including expanding service offerings and leveraging the Titan XT platform to drive future revenue growth.
Pre‑market trading saw Omnicell’s shares fall 14.69% as investors reacted to the EPS miss and guidance below consensus, underscoring the market’s sensitivity to earnings beats and margin expectations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.